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Summary To design hybrid tumour necrosis factor-a (TNF-a) applicable to systemic anti-tumour therapeutic
use, we assessed the relationships among the molecular size of hybrid TNF-a, in vitro bioactivity and in vivo
anti-tumour potency. Natural human TNF-a was covalently modified with polyethylene glycol (PEG) of
various number-average molecular weights (Mn= 2000, 5000, 12 000). The in vitro bioactivity of PEG-
modified TNF-as decreased with an increase in the degree of PEG modification, irrespective of the molecular
weight of PEG. This decrease in the specific bioactivity markedly increased with an increase in the molecular
weight of the attached PEG. The in vivo anti-tumour effects of the hybrid TNF-cxs with a molecular size from
100 to 110 kDa, which had more than 50% of specific bioactivity of native TNF-a, were significantly superior
to other PEG-TNF-as. These hybrid TNF-as showed over ten times greater anti-tumour effects than native
TNF-a. Thus, the molecular size, which was determined by the degree of PEG modification and PEG
molecular weight, influences the specific activity and anti-tumour effects of hybrid TNF-a.
Keywords: tumour necrosis factor-a; polyethylene glycol; molecular design; degree of modification; molecular
size; molecular weight
Tumour necrosis factor-a (TNF-a), an anti-tumour cytokine
produced by activated macrophages, has numerous biological
effects, such as direct cytotoxicity against tumour cells,
activation of immune anti-tumour response and selective
impairment of tumour blood vessels (Nobuhara et al., 1987;
Debs et al., 1990). Although TNF-a has been considered as a
novel anti-tumour drug, its therapeutic application as a single
and systemic anti-tumour agent is limited by the toxic side-
effects revealed by clinical trials (Blick et al., 1987; Spriggs et
al., 1988; Moritz et al., 1989). TNF-a has therefore been
therapeutically assessed in combination with other anti-
tumour cytokines to treat several tumours, and synergistic
effects have been identified (Zimmerman et al., 1989). More
recently, evidence has been accumulated that the adverse
side-effects of TNF-a are substantially enhanced by its
combination with interferon-y and interleukin-2, when
systemically administered (Smith et al., 1991; Yang et al.,
1991; Schiller et al., 1992). Nowadays, the clinical application
of TNF-a is limited to intratumoral administration, and its
clinical consequence is unfavourable (Pfreundschuh et al.,
1989; Lienard et al., 1992).
Chemical modification of bioactive proteins with poly-
ethylene glycol (PEG) increases their molecular size and steric
hindrance, both of which are derived from PEG attached to
bioactive proteins, resulting in augmented plasma half-lives
and stability (Katre et al., 1987; Hershfield et al., 1991).
These PEG-modified bioactive proteins have increased
therapeutic potency, so PEGylation enables the therapeutic
dose and frequency to be decreased. Thus, it seems that
PEGylation of biological proteins is one of the most useful
strategies to increase markedly their therapeutic efficacy and
effectively reduce their toxic side-effects. However, clinical
application of PEG-modified bioactive proteins has been
limited as yet. This limitation of clinical application is due to
the following reasons: 1) the increase in the molecular size of
bioactive proteins by PEGylation restricts their distribution
from blood to target tissues as well as increases their plasma
half-lives; 2) steric hindrance not only protects bioactive
proteins from attack by various proteinases, but also inhibits
their receptor binding. We previously assessed the relation-
ship between the molecular size of PEG-modified TNF-a,
steric hindrance and bioactivity to design a hybrid TNF-a
applicable to clinical use (Tsutsumi et al., 1995a). As a result,
the optimal modification of TNF-a with PEG (PEG5000;
number-average molecular weight, 5000) markedly and
selectively increased its anti-tumour potency and effectively
reduced its systemic toxic side-effects (Tsutsumi et al., 1995a).
In particular, MPEG-TNF-a, in which 56% of the lysine
amino groups of TNF-a were coupled with PEG50,, had
more than 10-fold greater anti-tumour potency than native
TNF-a, and several intravenous administrations of MPEG-
TNF-a alone completely regressed Meth-A solid tumours in
all treated mice without any TNF-a-mediated side-effects
(Tsutsumi et al., 1994). However, as pointed out in the
previous report (Tsutsumi et al., 1995a), more detailed studies
of the relationship between the molecular size of hybrid
TNF-a and its in vivo anti-tumour potency are necessary to
design a more anti-tumour active hybrid TNF-a. We
indicated that the molecular size of hybrid TNF-cx, which is
determined by the steric hindrance resulting from the
molecular weight of attached PEG and the degree of PEG
modification, may influence its specific activity and in vivo
anti-tumour activity.
Here, we attempted to optimise the PEGylation of TNF-a
to increase its anti-tumour potency. Hybrid TNF-as were
synthesised with PEG of various molecular weights and
separated into various molecular size fractions to study the
relationship between the molecular size of hybrid TNF-oe, in
vitro bioactivity and in vivo anti-tumour potency. This study
provides the information necessary to design a hybrid TNF-a
optimally suitable for therapeutic use.
Materials and methods
Materials
Natural human TNF-a was kindly supplied by Hayashibara
Biological Laboratories Inc. (Okayama, Japan). N-succinimi-
dyl succinate monomethoxy polyethylene glycol (activated
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1996PEG; number-average molecular weights = 2000, 5000 and
12 000) were supplied by Nippon Oil and Fats (Tokyo,
Japan). Other reagents and solvents were of analytical grade.
Animals and cells
Male ddY mice (5 weeks old) were purchased from SLC
(Hamamatsu, Japan). L-M cells were generously provided
by Mochida Pharmaceutical Co., Ltd. (Tokyo, Japan). L-M
cells were serially subcultured in Eagle's minimum essential
medium containing 10% fetal calf serum (FCS; Filtron,
Brooklyn, USA). Sarcoma-180 cells were maintained
intraperitoneally by serial passages in male ddY mice.
Preparation of PEG-modified TNF-a
PEG-modified TNF-oa (PEG-TNF-ax) was prepared as
described elsewhere (Tsutsumi et al., 1995a). Briefly, TNF-cx
in 0.2 M phosphate buffer, pH 7.2, was reacted with a 60-fold
molar excess of activated PEG at room temperature for
30 min. The reaction was stopped by adding a 5-fold molar
excess of e-amino-caproic acid over the activated PEG. The
resulting PEG-TNF-ax was purified and separated into
fractions of various molecular weights by gel filtration
chromatography (GFC: TSKgel G3000SWXL, Tosoh, To-
kyo, Japan; GFC-buffer: 0.2 M phosphate buffer, pH 7.2).
The molecular size of separated PEG-TNF-as was estimated
by GFC analysis, and the degree of PEG modification was
calculated from the molecular size of PEG-TNF-oc. The
protein concentration of native TNF-cx and PEG-TNF-as was
determined from absorbance at 280 nm, at which PEG has
no absorption. The specific activities of native TNF-a and
PEG-TNF-as were measured by the cytotoxic activity against
L-M cells as described by Yamazaki et al. (1986), and were
expressed in terms of Japan reference unit (JRU) defined
previously (Yamazaki et al., 1986).
Evaluation ofin vivo anti-tumour effect
Sarcoma-180 (S-180) cells (4 x 105) were implanted intrader-
mally in the abdomen of 5-week-old male ddY mice. After 7
days, when the tumour nodules had grown to 8-9 mm in
diameter, native TNF-ac and PEG-TNF-cxs were given as a
single intravenous injection. Drug efficacy against S-180 was
expressed as mean tumour volume, scores of tumour
haemorrhagic necrosis and tumour regrowth delay. Tumour
volume was calculated by the formula described by Haranaka
et al. (1984). Tumour haemorrhagic necrosis was scored
according to the method described by Carswell et al. (1975)
24 h after injection. Briefly, the maximal necrotic response
(score 3) indicates that 50% or more of the tumour mass is
necrotic, the moderate response (score 2) 25-50% necrotic,
the minimal response (score 1) less than 25% necrotic, and
no response (score 0) no visible necrosis. Tumour regrowth
delay was taken as the difference in time for treated and
control tumours to reach four times pretreatment tumour
volume (Braunschweiger et al., 1988).
Statistical analysis
Statistical evaluations of tumour volume, tumour haemor-
rhagic necrosis score and regrowth delay were analysed by
the Student's t-test.
Results
Preparation and in vitro bioactivity of PEG-TNF-oas
Natural human TNF-a was chemically modified by end point
attachment with PEG ofvarious molecular weights (number-
average molecular weight = 2000, 5000 and 12 000) via the
formation of an amino bond between lysine amino groups of
TNF-a and the terminal succinimidyl succinate group ofPEG.
The synthetic PEG-TNF-a was purified and size-fractionated
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by GFC, to assess the relationship between the molecular size
of PEG-TNF-a and bioactivity. Table I summarises the
molecular size, the degree of PEG modification and the
remaining bioactivity of separated PEG20N,-TNF-as. Even
after extensive modification of TNF-ax with PEG20W, TNF-ax
bioactivity was retained. Table II summarises the molecular
size, the degree of PEG modification and the remaining
bioactivity of separated PEG12000-TNF-cxs. The coupling
reaction between TNF-a and PGE,2 000 was remarkably
limited, and the maximal degree of PEG modification was
only 36%. This phenomenon was also observed with a longer
reaction time and the higher concentration of PEG12ON
relative to TNF-oa (data not shown), probably caused by the
steric hindrance derived from PEG,2 o attached to TNF-cx. In
addition, PEG,2000-TNFx Fr.1, in which only 36% of total
lysine-amino groups of TNF-a were coupled with PEG,200
(characterised in Table II), almost lost bioactivity in vitro.
Figure la shows the effect of the molecular weight ofPEG on
the relationship between the degree of PEG modification and
the remaining bioactivity of PEG-TNF-cs. The PEG500,-TNF-
a data from our previous study are also included (Tsutsumi et
al., 1995a). The remaining bioactivity of PEG-TNF-cxs
decreased with an increasing degree of PEG modification,
and the downward rates were marked in proportion to the
PEG molecular weight. Figure lb shows the relationship
between the molecular size of PEG-TNF-cxs and their
bioactivity. When PEG-TNF-axs were the same molecular
size, the TNF-a modified with higher molecular weight PEG
had a higher bioactivity than when modified with lower
molecular weight PEG.
In vivo anti-tumour effect of PEG-TNF-as
The anti-tumour effects of a single i.v. injection of PEG-
TNF-as on S-180 solid tumours were compared with that of
Table I Characterisation of PEG2000-modified TNF-os
Degree of Specific
PEG bioactivityc
modificationb (x 105 JRU
Molecular sizea (%) mg-'TNF)
PEG2000- 94 000 100 8.54+0.6
TNF-a Fr.1
PEG2000- 85 000 74 11.2+0.1
TNF-oa Fr.2
PEG2000- 75 000 48 15.2+2.9
TNF-a Fr.3
PEG2000- 66 000 22 19.5+2.7
TNF-a Fr.4
Native TNF-a 58 000 0 22.3 + 0.2
aDetermined by GFC (protein standard). bCalculated from
molecular size. CAssessed by the growth inhibition L - M tumour
cell assay.
Table II Characterisation of PEG12 000-modified TNF-as
Degree of Specific
PEG- bioactivityc
Molecular modificationb (x JO5JRU
sizea (%) mg-TNF)
PEG12000- 136 000 36 2.88±0.1
TNF-a Fr.1
PEG12000- 118 000 28 10.3+0.3
TNF-cx Fr.2
PEG12 ooo- 104 000 21 19.1 +1.1
TNF-a Fr.3
PEG12 000- 85 000 12 21.7+0.7
TNF-a Fr.4
Native TNF-ac 58 000 0 22.3 ±0.2
aDete,-ined by GFC (orotein standard). ba 'Determined by GFC (protein standard). bCalculated from
molecular size.
cell assay.
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native TNF-oc. S-180 cells were implanted intradermally and
tumour nodules reached to 8-9 mm in diameter on day 7.
Native TNF-a dose-dependently induced tumour-haemorrha-
gic necrosis at 24 h after i.v. injection on day 7 (Figure 2). All
of the PEG-TNF-as were intravenously injected at a dose of
1000 JRU per mouse. We reported that MPEG-TNF-c, in
which 56% of the total lysine-amino groups of TNF-oa were
coupled with PEG5100, had the most potent anti-tumour
activity among the PEG5000-TNF-cxs (Tsutsumi et al., 1995a).
The molecular size of this MPEG-TNF-a and its remaining
bioactivity were 108 000 and 52.3% of native TNF-ax
respectively. The necrotic score of MPEG-TNF-a at a dose
of 1000 JRU per mouse was significantly and markedly
higher than that of native TNF-cx at a dose of 10 000 JRU
per mouse. In contrast, PEG2WO-TNF-as had tumour
necrosis-induced potency similar to that of native TNF-oc at
a dose of 2000 JRU per mouse. PEG12000-TNF-os (1000 JRU
per mouse) had increased anti-tumour potency compared
with native TNF-a (2000 JRU per mouse). In particular,
PEG12000-TNF-ox Fr.3 (characterised in Table II) at a dose of
b
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Figure 1 Effect of the degree ofPEG modification and molecular
size of PEG-modified TNF-ocs on its bioactivity. Each value is
mean+s.d. (n =4). (a) Relationship between the bioactivity of
TNF-a and the degree of PEG modification; (b) relationship
between the bioactivity of TNF-a and the molecular size.
a
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Figure 2 Tumour necrotic effects of native TNF-cx and PEG-
modified TNF-as on S-180 solid tumours. Mice were used in
groups of more than seven. Values are means+s.e. Significant
difference from the group given 2000 JRU of native TNF-a
(*P<0.02), and 10000 JRU of native TNF-a (**P<0.05). ND,
not detected.
b
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Figure 3 Anti-tumour effect ofPEG2000- and PEG12 000-TNF-as on S-180 solid tumour. Single intravenous injection doses of PEG-
TNF-as and native TNF-ac were 1000 JRU per mouse. Mice were used in groups of more than seven. Each value is mean+s.e.
Statistical significance compared with saline control: *P<0.001.
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1000 JRU per mouse had higher anti-tumour potency than
native TNF-a at a dose of 10 000 JRU per mouse, so
PEG12 000-TNF-o Fr.3 was over 10-fold more potent than
native TNF-ca. Figure 3 shows the growth-inhibitory effects of
native TNF-a and PEG-TNF-axs at a dose of 1000 JRU
against S-180 solid tumour. Native TNF-a and PEG2000-TNF-
as did not inhibit tumour growth. MPEG-TNF-a drastically
inhibited tumour growth in spite of a single i.v. injection of
MPEG-TNF-oe alone. PEG12000-TNF-a Fr.2 and Fr.4 were
slightly more effective than native TNF-oa, and PEG12000-
TNF-a Fr.3 had a similar effect to MPEG-TNF-a. As shown
in Table III, complete regression occurred in one of the nine
mice given PEG12 o-TNF-cx Fr.3 and two of the nine mice
given MPEG-TNF-a. Significant regrowth delay was
observed in S-180 solid tumour after a single PEG12oo-
TNF-o Fr.3 or MPEG-TNF-a treatment (1000 JRU per
mouse). All the mice administered with native TNF-a at a
dose of 10 000 JRU developed piloerection, tissue inflamma-
tion and a transient decrease in body weight during the
experimental period (data not shown). But PEG12000-TNF-oi
Fr.3 and MPEG-TNF-a were tolerated well and the body
weight was not reduced.
Discussion
We previously assessed the relationship between the
molecular size of PEG5000-modified TNF-oa, steric hindrance
and bioactivity to design hybrid TNF-c optimally (Tsutsumi
et al., 1995a). We found that optimally modifying TNF-ax
with PEG markedly increased its bioavailability. But more
detailed studies on the relationship between the molecular
size of hybrid TNF-ax and its bioactivity were required to
optimise the modification of TNF-ax. In this study, we
attempted to discover the optimal molecular size of PEG-
TNF-a, which is determined by the degree of PEG
modification and the molecular weight of the attached PEG.
Up to this time, bioactive proteins have been modified
using PEG5000 without any theoretical basis in fact. Few
investigators studied the relationship between the bioactivity
of modified proteins and molecular size, although various
PEG-modified bioactive proteins have been extensively
studied. The remaining bioactivity of PEG-TNF-as de-
creased with increasing PEG modification, that is, the
molecular size of PEG-TNF-as (Figure la and b). This
phenomenon has also been found in PEG-modified inter-
leukin 6 (Tsutsumi et al., 1995b). In addition, the tendency of
the remaining bioactivity of PEG-TNF-axs to decrease was
marked when the molecular weight of the attached PEG was
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increased. Our preliminary studies on PEG-modified inter-
leukin 6 yielded similar results, but there are no other reports.
In contrast, we previously suggested that the enzymic activity
of PEG-modified superoxide dismutase (SOD) was gradually
reduced with increases in the degree of PEG modification,
irrespective of the molecular weight of attached PEG
(Tsutsumi et al., 1995c). The steric hindrance caused by the
PEG attached to SOD did not affect its enzymic activity
because its substrate is very small, so the enzymic activity of
PEG-SOD was only dependent upon the number of PEG
molecules attached to active regions. However, an exhibition
of TNF-a bioactivities requires its binding to its receptor
which has an extremely complicated steric structure. Thus,
the decrease in the specific bioactivity of PEG-TNF-a is
caused not only by PEG modification to binding site of TNF
receptor but also by steric hindrance derived from the
attached PEG. Similar results were also reported by
Yoshinaga et al. (1987). Additionally, the progress of the
coupling reaction between TNF-oa and PEG12 000 was
extremely limited, probably due to steric hindrance caused
by early attached PEG12 0 molecules. These results strongly
indicated that the molecular size of PEG-TNF-ac, that is, the
steric hindrance determined by the degree of PEG modifica-
tion as well as the molecular weight of PEG, is a very
important factor to consider in designing hybrid TNF-x.
In vivo anti-tumour potencies were evaluated by a single
intravenous administration of PEG-TNF-ac alone (Figures 2
and 3, Table III). All of PEG20W-TNF-xs had slightly
enhanced anti-tumour activity compared with native TNF-
a. LPEG-TNF-a (molecular size, 84 000), in which 29% of
the total lysine-amino groups of TNF-oa were coupled with
PEG500, had scarcely increased anti-tumour potency due to a
hardly enhanced plasma half-life in comparison with native
TNF-c, whereas LPEG-TNF-a had extremely high specific
bioactivity (Tsutsumi et al., 1995a). The molecular size of the
synthetic PEG2000-TNF-as was only 94 000 by even maximal
PEG modification. Indeed, the chemical modification of
TNF-cx with PEG2o increased its molecular size, but this was
thought not large enough to alter significantly the half-life of
TNF-a. That is, we thought that the degree of in vivo drug
effects is closely associated with the systemic relationship
among the remaining activity (specific activity), blood stasis,
proteinase resistance and transfer to the tumour tissue. As a
result, in vivo activity of all PEG2000-TNF-as was similar. In
contrast, PEG12o-TNF-as had enhanced anti-tumour
potency (Figure 2), and PEG12o-TNF-a Fr.3 (molecular
size, 104 000; remaining bioactivity, 85.7%) had anti-tumour
potency over 10-fold greater than that of native TNF-oa
(Figures 2 and 3, Table III). MPEG-TNF-ac (molecular size,
Table III Anti-tumour effect of native TNF-a and PEG-modified TNF-as
Single i.v. injection dose
(JRU per mouse)
Regrowth delay'
(days)
0+0.29
0.24+0.30
Complete
regressionb
0/9
0/7
Native TNF-a 1000 0.22±0.38 0/9
2000 1.00 +0.37 0/9
5000 1.11 +0.44 0/9
10 000 8.34+0.55 0/9
MPEG-TNF-ax 1000 > 17.4* ** 2/9
PEG12000-TNF-a Fr. 1 1000 0.67±0.29 0/9
Fr.2 1000 4.23 0.38 0/9
Fr.3 1000 > 12.4*.** 1/9
Fr.4 1000 3.56+0.45 0/7
PEG2000-TNF-a Fr. 1 1000 0.34 +0.33 0/9
Fr.2 1000 0.78 + 0.48 0/9
Fr.3 1000 0.11 +0.38 0/9
Fr.4 1000 0.23 0.38 0/9
aRegrowth delay was taken as the difference in time for treated and control tumours to reach
four times pretreatment tumour volume (n>7, mean ±s.e.). bComplete regression was defined
when tumour was not regrown for more than 150 days. Statistical significance compared with
saline control: *P<0.01, and with native TNF-a (10 000 JRU): **P<0.05.
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108 000; remaining bioactivity, 52.3%), in which 56% of the
total lysine-amino groups of TNF-a were coupled with
PEG5000, was also over ten times more potent than native
TNF-a (Figure 2). MPEG-TNF-a showed about 40 times
longer plasma half-life than native TNF-a (Tsutsumi et al.,
1995a), and Meth-A solid tumour was completely regressed
in all treated mice without any adverse side-effects by plural
intravenous administration of MPEG-TNF-cx alone (Tsutsu-
mi et al., 1994). We believe that PEG12000-TNF-o Fr.3 has a
markedly prolonged plasma half-life, resulting in an increase
in the anti-tumour potency. The complete regression of the S-
180 solid tumour in mice may be achieved by plural
intravenous injection of PEG12000-TNF-a Fr.3 and MPEG-
TNF-oa in all treated mice. We found that PEG-TNF-a
ranging from 100 to 110 kDa, whose specific bioactivity
remained above 50% in comparison with native TNF-ax, was
the most optimal PEGylation product. A higher specific
bioactivity of PEG-TNF-ax may result in a stronger anti-
tumour effect as a matter of course, but it was unclear why
PEG-TNF-a with a molecular size from 100 to 110 kDa was
more anti-tumour potent than other PEG-TNF-axs. In
general, the vascular permeability of tumours is enhanced
in comparison with normal tissues, and macromolecules with
a molecular size similar to that of albumin markedly
accumulate in tumour tissues (Imoto et al., 1992). In
addition, tumour-vascular permeability is selectively in-
creased by TNF-a (Umeno et al., 1994). Thus, PEG12 ooo-
TNF-ac Fr.3 and MPEG-TNF-ax might be selectively
distributed to tumour tissues. However, more detailed
studies on the pharmacokinetics of PEG-TNF-as are
necessary to clarify our speculation, and these are currently
under investigation. Until now, the clinical application of
TNF-x as a systemic anti-tumour agent has been quite
limited due to adverse toxic side-effects. Furthermore, the
therapeutic efficacy of TNF-a alone has not lived up to
expectations (Creaven et al., 1987; Kimura et al., 1987).
Therefore, cancer therapy with TNF-a has only been
proceeded by intratumoral administration in combination
with other anti-tumour drugs (Pfreundschuh et al., 1989;
Lienard et al., 1992). A single intravenous administration of
PEG12000-TNF-a Fr.3 or MPEG-TNF-cx alone induced
marked anti-tumour effects without TNF-a-mediated side-
effects. Thus, we believe that PEG12000-TNF-a Fr.3 or
MPEG-TNF-a are potential systemic anti-tumour therapeu-
tic drugs.
We suggest that the molecular size of PEG-modified
bioactive proteins, that is, steric hindrance determined by not
only the degree of PEG modification but also the molecular
weight of the attached PEG, may affect their clinical potency.
To design optimal hybrid bioactive proteins, knowledge of
the optimal molecular size should be a primary concern
regarding each bioactive protein. Our results will enable the
design of hybrid bioactive proteins suitable for clinical
therapeutic use.
Abbreviations
TNF-a, Tumour necrosis factor-a; PEG, polyethylene glycol; PEG-
TNF-a, PEG-modified TNF-ac.
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